- KR₩386bn
- KR₩298bn
- KR₩201bn
Brief: Bukwang Pharm Q1 Operating Profit 1 Billion Won, Down 62.6% From Year Earlier
Brief: Bukwang Pharmaceutical Ind Q3 Operating Profit 979 Million Won, Down 69.3% From Year Earlier
Brief: Bukwang Pharmaceutical Ind Q2 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Bukwang Pharmaceutical Ind Q1 Operating Profit 3 Billion Won, Swings To Profit From Year Earlier
Brief: Bukwang Pharmaceutical Ind To Conduct Capital Increase Of 100 Billion Won
Brief: Bukwang Pharmaceutical Q2 Operating Loss 2.5 Billion Won
Brief: Bukwang Pharmaceutical Ind Receives Market Approval For Its New Atypical Antipsychotic Drug ‘Latuda Tablets’ From South Korea’S Ministry Of Food And Drug Safety
Brief: Bukwang Pharm To Buy Back 50 Bln Won Worth Of (Its Treasury) Shares
Brief: Bukwang Pharm to sell 1.5 mln shares at 28,364 won/share
Brief: Bukwang Pharm says annual stock dividend for FY 2017
Brief: Bukwang Pharmaceutical Ind says annual stock dividend for 2016
Brief: Bukwang Pharmaceutical Ind says annual cash dividend for 2016